Hope Johnson and colleagues calculate the global and regional burden of serotype-specific pneumococcal disease in children under the age of five

A Fenoll

B Efron

CG Whitney

DGE Constenla

GD Rodenburg

Hope L. Johnson

IH Park

J Eskola

JL Fleiss

Jonathan Cohen

Katherine L. O'Brien

KL O'Brien

Larry R. Muenz

Laura Freimanis Hance

M Imöhl

Maria Deloria-Knoll

MD Knoll

Orin S. Levine

OS Levine

R Dagan

R DerSimonian

R Lagos

Richard Reithinger

S Yaro

Sonia K. Stoszek

T Cherian

TN Winther

WP Hausdorff

English

PubMed

Approximately 800,000 children die each year due to pneumococcal disease and >90% of these deaths occur in developing countries where few children have access to life-saving serotype-based vaccines. Understanding the serotype epidemiology of invasive pneumococcal disease (IPD) among children is necessary for vaccine development and introduction policies. The aim of this study was to systematically estimate the global and regional distributions of serotypes causing IPD in children <5 years of age.We systematically reviewed studies with IPD serotype data among children <5 years of age from the published literature and unpublished data provided by researchers. Studies conducted prior to pneumococcal conjugate vaccine (PCV) introduction, from 1980 to 2007, with ≥12 months of surveillance, and reporting ≥20 serotyped isolates were included. Serotype-specific proportions were pooled in a random effects meta-analysis and combined with PD incidence and mortality estimates to infer global and regional serotype-specific PD burden. Of 1,292, studies reviewed, 169 were included comprising 60,090 isolates from 70 countries. Globally and regionally, six to 11 serotypes accounted for ≥70% of IPD. Seven serotypes (1, 5, 6A, 6B, 14, 19F, 23F) were the most common globally; and based on year 2000 incidence and mortality estimates these seven serotypes accounted for >300,000 deaths in Africa and 200,000 deaths in Asia. Serotypes included in both the 10- and 13-valent PCVs accounted for 10 million cases and 600,000 deaths worldwide.A limited number of serotypes cause most IPD worldwide. The serotypes included in existing PCV formulations account for 49%–88% of deaths in Africa and Asia where PD morbidity and mortality are the highest, but few children have access to these life-saving vaccines.Please see later in the article for the Editors' Summar

Johnson Hope L.

Deloria-Knoll Maria

Levine Orin S.

Stoszek Sonia K.

Freimanis Hance Laura

Reithinger Richard

Muenz Larry R.

O'Brien Katherine L.

Public Library of Science (PLOS)

Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project

Approximately 800,000 children die each year due to pneumococcal disease and >90% of these deaths occur in developing countries where few children have access to life-saving serotype-based vaccines. Understanding the serotype epidemiology of invasive pneumococcal disease (IPD) among children is necessary for vaccine development and introduction policies. The aim of this study was to systematically estimate the global and regional distributions of serotypes causing IPD in children 300,000 deaths in Africa and 200,000 deaths in Asia. Serotypes included in both the 10- and 13-valent PCVs accounted for 10 million cases and 600,000 deaths worldwide. A limited number of serotypes cause most IPD worldwide. The serotypes included in existing PCV formulations account for 49%-88% of deaths in Africa and Asia where PD morbidity and mortality are the highest, but few children have access to these life-saving vaccines. Please see later in the article for the Editors' Summary

Hope L Johnson

Orin S Levine

Sonia K Stoszek

Larry R Muenz

Katherine L O'Brien

Directory of Open Access Journals

PLoS Medicine

Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project.

Crossref

Age- and serotype-specific pediatric invasive pneumococcal disease: insights from systematic surveillance in

An introduction to the bootstrap.

Clinical evaluation of new pneumococcal vaccines: the Finnish approach.

Decline in invasive pneumococcal disease after the introduction of proteinpolysaccharide conjugate vaccine.

Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae.

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.

Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.

Epidemiological and molecular characteristics of a highly lethal pneumococcal meningitis epidemic in Burkina Faso.

General Assembly, 56th session. Road map towards the implementation of the United Nations millennium declaration: report of the Secretary-General

Genetic basis for the new pneumococcal serotype, 6C.

Invasive pneumococcal disease in Danish children, 1996–2007, prior to the introduction of heptavalent pneumococcal conjugate vaccine.

Meta-analysis in clinical trials.

Pneumococcal Regional Serotype Distribution for Pneumococcal TPP.

Progress and future challenges in coordinated surveillance and detection of pneumococcal and Hib disease in developing countries.

Revision Analytical Report. Available:

Serotype replacement in perspective.

Standardizing surveillance of pneumococcal disease.

Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from

Temporal variations among invasive pneumococcal disease serotypes in children and adults in

The burden of pneumococcal disease and cost-effectiveness of a pneumococcal vaccine in Latin America and the Caribbean: a review of the evidence and a preliminary economic analysis.

The design and analysis of clinical experiments.

The global burden of disease due to Streptococcus pneumoniae in children less than 5 years of age.

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries,

World Health Organization

file:///data/remote/core/dit/data/public_library_of_science/pdf/a77/ZnRwOi8vZnRwLm5jYmkubmxtLm5paC5nb3YvcHViL3BtYy9vYV9wYWNrYWdlLzAyL2NjL1BNQzI5NTAxMzIudGFyLmd6.pdf

Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project

Abstract

Similar works

Full text

Available Versions

Public Library of Science (PLOS)

Public Library of Science (PLOS)

Directory of Open Access Journals

Crossref